Physician profile
Danielle M Abel
NPI 1255751731
$9,040.57
in general payments reported to CMS, 2019-2025
18 companies · $1,727 in 2025
The $1,727 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,075 · 2022: $1,532 · 2023: $2,080 · 2024: $2,626 · 2025: $1,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,100 · Education: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,099.67 |
| Education | $333.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,355.83 | 2021-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $1,618.40 | 2021-2025 | |
| Abbvie INC. | $1,242.26 | 2021-2025 | Skyrizi, Humira |
| E.R. Squibb & Sons, L.L.C. | $649.34 | 2022-2025 | Sotyktu |
| Amgen INC. | $624.85 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $569.10 | 2021-2025 | |
| Lilly USA, LLC | $546.71 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $337.93 | 2021-2025 | Dupixent |
| Pfizer INC. | $331.04 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $213.34 | 2023-2025 | Zoryve |
| Ucb, INC. | $211.57 | 2024-2025 | Bimzelx |
| Incyte Corporation | $118.84 | 2023-2024 | Opzelura |
| Sun Pharmaceutical Industries INC. | $81.25 | 2022-2025 | Winlevi |
| Mayne Pharma Commercial LLC | $40.30 | 2025 | |
| Janssen Scientific Affairs, LLC | $34.99 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $26.70 | 2025 | Anzupgo |
| Verrica Pharmaceuticals INC. | $23.98 | 2025 | Ycanth |
| Dermavant Sciences, INC. | $14.14 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Abel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.